Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» SMA
SMA
Biogen ramps up its SMA rivalry with Novartis with new Spinraza trial
Fierce Pharma
Wed, 09/18/19 - 11:21 am
Biogen
clinical trials
Spinraza
SMA
spinal muscular atrophy
Novartis
5 Biggest New Drugs Approved in 2019 So Far
Motley Fool
Tue, 08/13/19 - 11:43 am
drug approvals
FDA
AbbVie
JNJ
Novartis
Pfizer
Skyrizi
psoriasis
Vyndaqel
Zolgensma
SMA
Mayzent
multiple sclerosis
Balversa
metastatic bladder cancer
Novartis’ Zolgensma Joins Growing List of Medicines to Lose Accelerated Assessment Status in EU
RAPS.org
Mon, 07/29/19 - 11:19 pm
Novartis
Zolgensma
CHMP
Europe
SMA
24 insurers have policies on coverage of world's most expensive drug
Beckers Hospital Review
Mon, 07/22/19 - 08:13 pm
Novartis
payers
insurance
Medicaid
SMA
drug pricing
Zolgensma
Payers, patients coming on board for Novartis’ Zolgensma
BioCentury
Thu, 07/18/19 - 05:58 pm
Novartis
Zolgensma
SMA
gene therapy
payers
patients
Novartis struggling to win payer coverage for $2.1M gene therapy Zolgensma: analysts
Fierce Pharma
Wed, 07/3/19 - 10:38 am
Novartis
Zolgensma
drug pricing
SMA
gene therapy
payers
Threats to Spinraza are mounting, but Biogen still has cards to play
EP Vantage
Mon, 07/1/19 - 07:25 pm
Biogen
SMA
Spinraza
Novartis
Roche
risdiplam
Zolgensma
Is $2.1 million too much for a drug? For affected parents, there is no debate
Stat
Mon, 06/3/19 - 11:28 am
Novartis
drug pricing
Zolgensma
SMA
Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
Motley Fool
Fri, 05/31/19 - 11:53 pm
Novartis
Zolgensma
SMA
gene therapy
Novartis gene therapy approved, but will come at cost of more than $2 million
Biopharma Dive
Fri, 05/24/19 - 11:45 pm
SMA
Novartis
drug pricing
Zolgensma
Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range
Yahoo/Reuters
Thu, 05/23/19 - 09:48 am
Novartis
Pharma CEOs
Vas Narasimhan
gene therapy
SMA
drug pricing
Zolgensma
SMA Moment: Will Gene Therapy Shift Treatment, Costs of Muscle Disease?
Xconomy
Thu, 05/2/19 - 11:00 am
gene therapy
SMA
spinal muscular atrophy
Novartis
Zolgensma
Novartis' star gene therapy faces potential safety issue following a recent infant death in study
Endpoints
Sun, 04/21/19 - 12:23 am
Novartis
Zolgensma
SMA
Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy
BioSpace
Mon, 01/14/19 - 11:55 pm
Massachusetts
Novartis
SMA
gene therapy
Kymriah
Novartis’ SMA Gene Therapy Is on the Fast Track for Approval
BioSpace
Mon, 12/3/18 - 05:55 pm
Novartis
gene therapy
SMA
AVXS-101
Zolgensma
priority review
FDA
US benefits manager baulks after Novartis values gene therapy at $4-5 mln
Yahoo/Reuters
Fri, 11/23/18 - 01:12 pm
Novartis
Express Scripts
SMA
spinal muscular atrophy
drug pricing
AVXS-101
Biogen's new Spinraza data for earlier use 'pretty amazing,' analyst says
Fierce Pharma
Mon, 10/8/18 - 11:37 pm
Biogen
Spinraza
spinal muscular atrophy
SMA
Biogen's Spinraza gets an early no-go from NICE
Biopharma Dive
Wed, 08/15/18 - 09:57 am
Biogen
UK
NICE
Spinraza
SMA
spinal muscular atrophy
Roche scraps €120M SMA drug after hitting ‘many difficulties’
Fierce Biotech
Fri, 06/1/18 - 11:25 pm
Roche
SMA
spinal muscular atrophy
Olesoxime
Biogen faces increased 'pressure' after AveXis buyout by Novartis
Marketwatch
Mon, 04/9/18 - 09:10 am
Novartis
AveXis
Biogen
SMA
M&A
AVXS-1-1
Spinraza
Pages
« first
‹ previous
1
2
3
4
5
next ›
last »